Valeant Pharmaceuticals

VRX-N

Analysis and Opinions about VRX-N

Signal
Opinion
Expert
COMMENT
COMMENT
December 19, 2017

They are in recovery mode. It’s all about managing debt at this point and doing that properly. Going back to the glorious years of what it was before will never happen. The chart looks fairly positive, looks like we’re in a breakout now. From his perspective we are not in a seasonal period for health care and pharmaceuticals at all, particularly in the new year. Yes, we’ve had this bit of breakout and had a little bit of an uptick. But watch out if the overall healthcare doesn’t do well and if we don’t have any news from Valeant, we might see that pull back down. He would be cautious and would actually wait until later on. Seasonally we’re not there.

Show full opinionHide full opinion

They are in recovery mode. It’s all about managing debt at this point and doing that properly. Going back to the glorious years of what it was before will never happen. The chart looks fairly positive, looks like we’re in a breakout now. From his perspective we are not in a seasonal period for health care and pharmaceuticals at all, particularly in the new year. Yes, we’ve had this bit of breakout and had a little bit of an uptick. But watch out if the overall healthcare doesn’t do well and if we don’t have any news from Valeant, we might see that pull back down. He would be cautious and would actually wait until later on. Seasonally we’re not there.

SPECULATIVE BUY
SPECULATIVE BUY
March 21, 2017

This is a huge problem child. Some of their drugs and compounds are worth a lot of money. He likes that sentiment has gotten so negative. Sometimes, when you have some enduring products, it is time to take a position as part of a diversified portfolio. Likes the new management. Their $30 million debt dwarfs the market cap which is why the earnings and sales look cheap. A high-risk situation.

Show full opinionHide full opinion

This is a huge problem child. Some of their drugs and compounds are worth a lot of money. He likes that sentiment has gotten so negative. Sometimes, when you have some enduring products, it is time to take a position as part of a diversified portfolio. Likes the new management. Their $30 million debt dwarfs the market cap which is why the earnings and sales look cheap. A high-risk situation.

COMMENT
COMMENT
March 13, 2017

Bill Ackman has just exited his position. He feels for people that had bought more on the way down. The company has been sitting with a B rating for quite a while, because the leverage of the balance sheet was used to buy companies that did not perform the way they were supposed to. In the last month or so, while the high-yield bonds have been rising in price, this stock has been going the other way. The bond market can usually signal something much stronger than what the equity market can understand. Debt to cash flow is huge. There are tens of billions of debt outstanding, so anything they do moving forward, they’ll have to continue to sell assets.

Show full opinionHide full opinion

Bill Ackman has just exited his position. He feels for people that had bought more on the way down. The company has been sitting with a B rating for quite a while, because the leverage of the balance sheet was used to buy companies that did not perform the way they were supposed to. In the last month or so, while the high-yield bonds have been rising in price, this stock has been going the other way. The bond market can usually signal something much stronger than what the equity market can understand. Debt to cash flow is huge. There are tens of billions of debt outstanding, so anything they do moving forward, they’ll have to continue to sell assets.

WAIT
WAIT
December 6, 2016

There is lots of value here, but until we get through the “woodshed process” by the Justice Department. They have a lot of goodwill on the books, but have good earnings which is a good thing. His model price is $57.93, a 190% upside. Let the process continue and let the write offs happen every quarter, and he’ll get a clearer picture of what is going on. It is too early yet.

Show full opinionHide full opinion

There is lots of value here, but until we get through the “woodshed process” by the Justice Department. They have a lot of goodwill on the books, but have good earnings which is a good thing. His model price is $57.93, a 190% upside. Let the process continue and let the write offs happen every quarter, and he’ll get a clearer picture of what is going on. It is too early yet.

COMMENT
COMMENT
June 16, 2016

Has been looking at things that are trading below their intrinsic value. Doesn’t own this, because it doesn’t have a dividend, but if he was thinking of opening up a new fund they gave him more degrees of freedom, he might think about looking at this. The company is going back to being a traditional biotech company and doing research and development. If they are successful in this 3-4 year journey and become a normal biotech company, there may be some value there. He doesn’t think it is going to zero.

Show full opinionHide full opinion

Has been looking at things that are trading below their intrinsic value. Doesn’t own this, because it doesn’t have a dividend, but if he was thinking of opening up a new fund they gave him more degrees of freedom, he might think about looking at this. The company is going back to being a traditional biotech company and doing research and development. If they are successful in this 3-4 year journey and become a normal biotech company, there may be some value there. He doesn’t think it is going to zero.

DON'T BUY
DON'T BUY
June 1, 2016

This company is really, really good. It is a beautiful company, but with the craziness that is going on right now, is the risk worth it? No! He would stay far away from this.

Show full opinionHide full opinion

This company is really, really good. It is a beautiful company, but with the craziness that is going on right now, is the risk worth it? No! He would stay far away from this.

HOLD
HOLD
February 23, 2012
A highflyer but the volatility is absolutely crazy. Had a big drop mid-2011. Seems to have support at around $45. There is deeper support at around $44. If it gets to $48, it will probably go a little bit higher and could then move back to the old high of $55.
Show full opinionHide full opinion
A highflyer but the volatility is absolutely crazy. Had a big drop mid-2011. Seems to have support at around $45. There is deeper support at around $44. If it gets to $48, it will probably go a little bit higher and could then move back to the old high of $55.
Showing 1 to 7 of 7 entries
  • «
  • 1
  • »

Valeant Pharmaceuticals(VRX-N) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for Valeant Pharmaceuticals is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Valeant Pharmaceuticals(VRX-N) Frequently Asked Questions

What is Valeant Pharmaceuticals stock symbol?

Valeant Pharmaceuticals is a OTC stock, trading under the symbol VRX-N on the (). It is usually referred to as or VRX-N

Is Valeant Pharmaceuticals a buy or a sell?

In the last year, there was no coverage of Valeant Pharmaceuticals published on Stockchase.

Is Valeant Pharmaceuticals a good investment or a top pick?

Valeant Pharmaceuticals was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Valeant Pharmaceuticals.

Why is Valeant Pharmaceuticals stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Valeant Pharmaceuticals worth watching?

In the last year, there was no coverage of Valeant Pharmaceuticals published on Stockchase.

What is Valeant Pharmaceuticals stock price?

On , Valeant Pharmaceuticals (VRX-N) stock closed at a price of $.